Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis
2006 ◽
Vol 27
(5)
◽
pp. 467-472
◽
1996 ◽
pp. 143-152
2016 ◽
Vol 36
(5)
◽
pp. 625-633
◽
2008 ◽
Vol 27
(10)
◽
pp. 1243-1248
◽
2014 ◽
Vol 31
(4)
◽
pp. 564-571
◽